MAKO Surgical Corp.  

(Public, NASDAQ:MAKO)   Watch this stock  
Find more results for mako
11.14
-0.07 (-0.62%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.03 - 11.49
52 week 10.00 - 27.18
Open 11.33
Vol / Avg. 816,486.00/1.07M
Mkt cap 522.95M
P/E     -
Div/yield     -
EPS -0.69
Shares 46.94M
Beta 0.48
Inst. own 63%
Jul 29, 2013
Q2 2013 MAKO SURGICAL CORP Earnings Release Add to calendar
Jun 4, 2013
MAKO SURGICAL CORP Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
May 7, 2013
Q1 2013 MAKO SURGICAL CORP Earnings Conference Call
May 7, 2013
Q1 2013 MAKO SURGICAL CORP Earnings Release
Feb 26, 2013
Q4 2012 MAKO SURGICAL CORP Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -38.78% -31.69%
Operating margin -35.99% -34.58%
EBITD margin - -25.93%
Return on average assets -23.82% -22.09%
Return on average equity -27.88% -26.98%
Employees 436 -
Carbon Disclosure Rating - -

Address

2555 Davie Road
FORT LAUDERDALE, FL 33317
United States - Map
+1-954-9272044 (Phone)
+1-954-9270446 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

MAKO Surgical Corp. (MAKO) is a medical device company that markets its robotic arm solution and orthopedic implants for orthopedic procedures called MAKOplasty. The Company offers MAKOplasty, a surgical solution that enables orthopedic surgeons to treat patient specific, osteoarthritic disease. MAKOplasty is performed using its RIO Robotic Arm Interactive Orthopedic system (RIO). The RIO is a technology platform that utilizes tactile guided robotic arm technology and patient specific planning and visualization to offer reproducible precision to surgeons. MAKOplasty procedures are enabled through its technology consisting of the components, which includes RIO system, MAKOplasty applications, and RESTORIS family of implant systems. The RIO is used to treat early to mid-stage osteoarthritic knee disease and osteoarthritic hip disease. During the year ended December 31, 2011, a total of 48 RIO systems were sold worldwide.

Officers and directors

Maurice R. Ferre M.D. Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Fritz L. LaPorte Chief Financial Officer, Senior Vice President - Finance and Administration, Treasurer
Age: 42
Bio & Compensation  - Reuters
Menashe R. Frank Senior Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Christopher R. Marrus Senior Vice President - Sales
Age: 46
Bio & Compensation  - Reuters
Ivan Delevic Senior Vice President - Marketing
Age: 46
Bio & Compensation  - Reuters
Lawrence T. Gibbons Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 60
Bio & Compensation  - Reuters
Richard Leparmentier Senior Vice President - Engineering
Age: 44
Bio & Compensation  - Reuters
Duncan H. Moffat Senior Vice President - Operations
Age: 51
Bio & Compensation  - Reuters
Charles W. Federico Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
S. Morry Blumenfeld Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters